Production (Stage)
Boundless Bio, Inc.
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.91% | 48.04% | 46.69% | 45.47% | 37.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.72% | 33.71% | 29.60% | 26.57% | 24.19% |
| Operating Income | -23.72% | -33.71% | -29.60% | -26.57% | -24.19% |
| Income Before Tax | -23.61% | -32.22% | -24.43% | -17.75% | -12.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.61% | -32.22% | -24.43% | -17.75% | -12.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.61% | -32.22% | -24.43% | -17.75% | -12.78% |
| EBIT | -23.72% | -33.71% | -29.60% | -26.57% | -24.19% |
| EBITDA | -23.85% | -34.07% | -29.97% | -26.98% | -24.61% |
| EPS Basic | 93.13% | 64.30% | 42.73% | 20.42% | -3.05% |
| Normalized Basic EPS | 93.13% | 64.30% | 42.73% | 20.42% | -3.05% |
| EPS Diluted | 93.13% | 64.30% | 42.73% | 20.42% | -3.05% |
| Normalized Diluted EPS | 93.13% | 64.30% | 42.73% | 20.42% | -3.05% |
| Average Basic Shares Outstanding | 1,699.90% | 1,294.88% | 880.44% | 452.39% | 9.34% |
| Average Diluted Shares Outstanding | 1,699.90% | 1,294.88% | 880.44% | 452.39% | 9.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |